Over 60 Abstracts Highlight Key Advances
BeOne Medicines Ltd. is making a significant impact at the upcoming 2026 American Society of Clinical Oncology (ASCO) Annual Meeting and the European Hematology Association (EHA) Congress with over 60 abstracts accepted for presentation. These events will take place from May 29 to June 2 in Chicago and from June 11 to 14 in Stockholm, respectively.
The company will showcase its leadership in hematologic malignancies, particularly in chronic lymphocytic leukemia (CLL), with presentations on foundational therapies and next-generation innovations. Key data will include long-term outcomes from the SEQUOIA trial, highlighting BRUKINSAae (zanubrutinib) as a foundational BTK inhibitor.
Amit Agarwal, M.D., Ph.D., Chief Medical Officer, Hematology at BeOne Medicines, emphasised, “Seventy-eight-month follow-up data from SEQUOIA underscore what it truly takes to lead in CLL over the long term: long-term efficacy, ability for sequencing treatments, and confidence in first-line treatment decisions.”
Advancements in CLL Treatment
New results from a subgroup analysis of SEQUOIA will be presented at EHA 2026, showing that patients aged 80 years or older benefit significantly, highlighting the therapy’s efficacy across varied age groups.
BeOne is also advancing its solid tumor research with presentations on seven unique assets. These include data on the PD-1 inhibitor TEVIMBRAae (tislelizumab) and the HER2-targeting agent ZIIHERAae (zanidatamab), which are pivotal in addressing unmet needs in lung, gastrointestinal, and other cancers.
Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors, remarked, “At ASCO 2026, we are demonstrating the strength of BeOne’s science, the scale of our pipeline, and the speed at which we are delivering innovation for patients.”
Updated data on BeOne’s foundational BTK degrader, BGB-16673, in patients with relapsed/refractory CLL, will be presented at EHA 2026. This includes promising results in BTK-naïve patients, making it the most advanced BTK degrader in clinical settings with over 1,100 patients dosed.
The all-oral combination of BeOne’s foundational BCL2 inhibitor sonrotoclax plus zanubrutinib (ZS) in CLL has demonstrated deep responses and unprecedented speed to undetectable MRD, showcasing durable remission.
An investor webcast will be hosted by BeOne on June 1, 2026, at 7:00 PM CDT. This event will cover clinical and corporate highlights from ASCO, providing updates on their global R&D pipeline.
